Randomized phase III placebo-controlled trial of carboplatin/paclitaxel (CP) with or without the vascular-disrupting agent vadimezan (ASA404) in advanced non-small cell lung cancer (NSCLC).
P. Lara
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
J. Douillard
Consultant or Advisory Role - Novartis
Honoraria - Novartis
K. Nakagawa
Consultant or Advisory Role - Novartis
J. Von Pawel
Consultant or Advisory Role - Antisoma; Novartis
M. J. McKeage
Consultant or Advisory Role - Antisoma; Novartis
Honoraria - Antisoma; Novartis
Research Funding - Antisoma; Novartis
I. Albert
No relevant relationships to disclose
G. Losonczy
No relevant relationships to disclose
M. Reck
Consultant or Advisory Role - AstraZeneca; Lilly; Pfizer; Roche
Honoraria - AstraZeneca; Lilly; Roche
D. S. Heo
No relevant relationships to disclose
X. Fan
Employment or Leadership Position - Novartis
A. Fandi
Employment or Leadership Position - Novartis
G. Scagliotti
Honoraria - AstraZeneca; Lilly; Roche